Urol. praxi. 2019;20(4):150-156 | DOI: 10.36290/uro.2019.068
Androgen deprivation therapy of prostate cancer and cardiovascular morbidity
- Urologická klinika VFN a 1. LF UK v Praze
Androgen deprivation therapy (ADT) of prostate cancer (PC) is burdened by a number of adverse events or effects (AEs). Immediate AEs are hot flashes and sweating, the main AE of long-term ADT include body feminisation, sexual and cognitive changes, fatigue or sleep disturbances. Other AEs are related to metabolic changes (osteoporosis, changes in lipid metabolism, insulin resistance and metabolic syndrome). Serious AEs include fractures and cardiovascular events (CVEs). Treatment with agonists of luteinizing hormone-releasing hormone (LHRH) is associated with a higher risk of CVEs compared to the LHRH antagonist degarelix. Higher rate of CVEs during therapy with LHRH agonists is most likely caused by a higher level of follicle stimulating hormone (FSH) which leads to a greater instability of atherosclerotic plaque. Randomized trials that will assess the effect of LHRH agonists and degarelix on the risk of CVEs are still active without the results available so far. Preventive measures during ADT for PC should target loss of weight, increased exercise, improved nutrition and smoking cessation.
Keywords: prostate cancer, androgen deprivation therapy, LHRH agonists, degarelix, cardiovascular events
Published: October 10, 2019 Show citation
References
- Zpráva o zdraví obyvatel České republiky. Ministerstvo zdravotnictví České republiky, Praha 2014. [online] [cit. 2019-07-19]. Dostupné z: http://www.mzcr.cz/verejne/Soubor.ashx?souborID=20954&typ=application/pdf&nazev=Zpr%C3%A1va%20o%20zdrav%C3%AD%20obyvatel%20%C4%8CR%202014.pdf.
- Mottet N, van der Bergh RCN, Briers E. EAU-EANM-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer 2019. [online] [cit. 2019-07-25]. Dostupné z: https://uroweb.org/guideline/prostate-cancer/.
- Matoušková M. Farmakoterapie karcinomu prostaty. Farmakoterapie 2006; 1(16): 84-90.
- Čapoun O. Hormonální prostředí prostaty a principy hormonální léčby. In: Matoušková M, Svoboda T, eds. Multimodální přístup k nádorům močového měchýře a prostaty. Olomouc: Solen; 2018: 182-192.
- Čapoun O. Konvenční hormonální léčba karcinomu prostaty. In: Marek Babjuk, Jindřich Fínek. Kastračně rezistentní karcinom prostaty. Farmakon Press, Praha 2017: 45-54.
- Qan'ir Y, DeDeaux D, Godley PA, Mayer DK, Song L. Management of Androgen Deprivation Therapy-Associated Hot Flashes in Men With Prostate Cancer. Oncol Nurs Forum. 2019; 46(4): E107-E118.
Go to PubMed... - Casey RG, Corcoran NM, Goldenberg SL. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl. 2012; 14(2): 226-231.
Go to original source... Go to PubMed... - Crawford ED, Schally AV, Pinthus JH, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017; 35(5): 183-191. Go to original source... Go to PubMed...
- Crawford ED, Schally AV, Eckel RH. Cardiometabolic Effects Associated With Androgen Deprivation Therapy: Potential Mechanism of Action. [online] [cit. 2019-07-26]. Dostupné z: https://grandroundsinurology.com/wp-content/uploads/2019/02/Cariometabolic-Effects-Associated-with-ADT.pdf
- Chen DY, See LC, Liu JR, et al. Risk of cardiovascular ischemic events after surgical castration and gonadotropin-releasing hormone agonist therapy for prostate cancer: a nationwide cohort study. J Clin Oncol. 2017; 35: 3697-3705. Go to original source...
- Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102(11): 1531-1538. Go to original source... Go to PubMed...
- Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014; 66(6): 1101-1108. Go to original source... Go to PubMed...
- Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014; 65(3): 565-573. Go to original source... Go to PubMed...
- Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease. J Urol. 2019 Jun 12:101097JU0000000000000384. Go to original source...
- Pinthus JH, Klotz L, Lukka H, et al. Cardiovascular disease characteristics of newly diagnosed prostate cancer patients: findings from the pilot phase of RADICAL PC: a prospective study of cardiovascular disease in men with prostate cancer. J Urol. 2017; 197: e163 448. Go to original source...
- A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE). [online] [cit. 2019-08-01]. Dostupné z: https://clinicaltrials.gov/ct2/show/NCT02663908.
- Merseburger A, Bro Falkenberg A, Kornilova OJ. New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk. World J Urol. 2019; 37(6): 1085-1093. Go to original source...